Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial...

Area of Science:

• Nephrology
• Pharmacology
• Biochemistry

Background:

• Cholestasis-associated renal injury, or cholemic nephropathy (CN), is a severe clinical issue with no specific pharmacological treatments.
• Oxidative stress and mitochondrial dysfunction are implicated in the pathogenesis of CN.
• Metformin, a widely used anti-diabetic medication, exhibits novel pharmacological properties, including beneficial effects on oxidative stress and mitochondrial function.

Purpose of the Study:

• To investigate the potential therapeutic effects of metformin in an animal model of cholestasis-associated renal injury.
• To evaluate metformin's impact on oxidative stress markers and mitochondrial function in the kidneys of cholestatic rats.

Main Methods:

• Rats underwent bile duct ligation (BDL) to induce cholestasis.
• Treated rats received metformin (250 and 500 mg/kg) daily for 14 days post-BDL.
• Kidney, urine, and serum samples were collected and analyzed for biochemical and histopathological changes.

Main Results:

• BDL rats exhibited elevated oxidative stress markers (ROS, lipid peroxidation, protein carbonylation) and depleted antioxidant capacity (GSH).
• Mitochondrial dysfunction was evident in BDL rats, indicated by impaired ATP levels, dehydrogenase activity, and membrane potential.
• Metformin treatment significantly reduced oxidative stress, improved mitochondrial indices, and mitigated renal histopathological damage, including tubular degeneration, inflammation, and fibrosis.

Conclusions:

• Metformin demonstrates significant nephroprotective effects in a rat model of cholestasis-associated renal injury.
• The therapeutic benefits of metformin in CN are attributed to its ability to mitigate oxidative stress and restore mitochondrial function.
• Metformin emerges as a potential candidate for managing cholemic nephropathy.